Results 231 to 240 of about 290,183 (300)

Functional Differences of Very-Low-Density Lipoprotein Receptor Splice Variants in Regulating Wnt Signaling. [PDF]

Mol Cell Biol, 2016
Chen Q, Takahashi Y, Oka K, Ma JX.
europepmc   +1 more source

Synergistic Effects of Normal‐Range Serum Sodium and Potassium on Mortality: The Modifying Role of Inflammation From a NHANES Cohort Analysis

Chronic Diseases and Translational Medicine, EarlyView.
Nonlinear associations of serum sodium levels with cardiovascular (A) and all‐cause mortality (B)among 32,837 adults. Nonlinear associations of serum potassium levels with cardiovascular (C) and all‐cause mortality (D) among 32,837 adults. ABSTRACT Background This study aimed to investigate the associations of serum sodium and potassium levels within ...
Haofeng Zhang, Fudong He, Zhenger Fang, Guangjun Zheng, Biying Zhou, Xia Chen, Mingliang Liu, Guang Hao   +7 more
wiley   +1 more source

A Stacked Ensemble Multi‐Label Model for Predicting Co‐Occurring Microvascular and Macrovascular Complications in Type 2 Diabetes

Chronic Diseases and Translational Medicine, EarlyView.
Feature importance for predicting multiple diabetes complications based on a Stacking‐Classifier Chain model. Abstract Background Type 2 diabetes mellitus (T2DM) leads to severe microvascular and macrovascular complications. Traditional single‐label prediction models fail to capture their co‐occurring nature.
Maryam Zamani, Maryam Farhadian, Nasrin Piran, Shiva Borzouei   +3 more
wiley   +1 more source

Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review

Chronic Diseases and Translational Medicine, EarlyView.
Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi, Shabnam Tariq, Kristian Arak, Mhd Alaa Aldin Al‐Haffar, Kyaw Thet, Ahmed H. Abdelhafiz   +5 more
wiley   +1 more source

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source